3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase EARLY_PHASE1
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
19
Colorectal Neoplasms
11
Brain Neoplasms
7
Colonic Neoplasms
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Rectal Neoplasms
2
Lung Neoplasms
2
Thyroid Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Interventions
aldesleukin
16
Cyclophosphamide
14
fludarabine phosphate
11
Interleukin-2
11
fludarabine
10
Nivolumab
7
pembrolizumab
5
cemiplimab
5
Ipilimumab
5
Temozolomide
4
Fluorouracil
4
Aminolevulinic Acid
4
sonidegib
3
Surgical Procedures, Operative
3
Radiotherapy
3
zanolimumab
2
trametinib
2
talabostat
2
montanide ISA 51
2
dabrafenib
2
Whole-Body Irradiation
2
Tablets
2
Semaxinib
2
Radiation
2
Petrolatum
2
Peptides
2
MART-1 Antigen
2
Gefitinib
2
Eflornithine
2
Cisplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Skin Neoplasms
×
encorafenib
×
Clear all
NCT05926960
2026-03-09
PORTSIDE
Pfizer
Phase 2
Terminated
38 enrolled